Efti/Keytruda combo future, where to?

Howdy everyone, been thinking about this for a while:
Immutep/Merck collaboration, Tacti 002 trial initiated by Immutep with Merck supplying $18M
worth of keytruda, with Immutep doing the rest....
Retail value of keytruda in USA is $150,000 per annum USD for monthly treatments costing $12,000USD.
OK, for this trial I doubt it would be supplied at retail, so I assume there is probably a $30M allowance
by Merck to give Immutep a chance to prove Efti is an advantage to keytruda in successfully treating patients.
Therefore, I wonder what is Mercks threshold, given other majors entering the same field, some already with Efti,
some without and will Merck bite the bullet and jump if next tacti-002 data is positive given the lure of patent status.
Personally, I think there is a better than even money chance, but that means nothing....
tuts, yd, Hodgie, coco et al, interested in your thoughts of what Mercks tipping point could be if any?